International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 335-342 , 1 October 2008

Report From the International Atomic Energy Agency (IAEA) Consultants' Meeting on Elective Nodal Irradiation in Lung Cancer: Non–Small-Cell Lung Cancer (NSCLC)

  • José S.A. Belderbos, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    • Corresponding Author InformationReprint requests to: J. S. A. Belderbos, M.D., Ph.D., Radiation Oncologist, Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis, Plesmanlaan 121, 1066 CX Amsterdam. Tel: +31 (020)-5122125; Fax: +31 (020)-6691101
    • ,
  • Lucyna Kepka, M.D.

      Affiliations

    • Department of Radiation Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    • ,
  • Feng-Ming (Spring) Kong, M.D., Ph.D., M.P.H.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    • ,
  • Mary K. Martel, Ph.D.

      Affiliations

    • Department of Radiation Oncology, The University Texas, Houston, TX
    • ,
  • Gregory M.M. Videtic, M.D., C.M., F.R.C.P.C.

      Affiliations

    • Department of Radiation Oncology, The Cleveland Clinic, Cleveland, OH
    • ,
  • Branislav Jeremic, M.D., Ph.D.

      Affiliations

    • International Atomic Energy Agency, Vienna, Austria

Received 7 March 2008 ,Revised 4 April 2008 ,Accepted 7 April 2008.

References 

  1. Delaney G, Barton M, Jacob S, et al. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol. 2003;4:120–128
  2. Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: An evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001;49:973–985
  3. Kong FM, Gaspar LE, Komaki R, et al. Patterns of practice in radiation dose prescription and treatment planning for patients with lung cancer among members of American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys. 2007;69:S483
  4. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1–9
  5. Bradley JD, Wahab S, Lockett MA, et al. Elective nodal failures are uncommon in medically inoperable patients with stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys. 2003;56:342–347
  6. Belderbos JS, Heemsbergen WD, De Jaeger K, et al. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126–134
  7. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324–333
  8. Zhao L, West BT, Hayman JA, et al. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;68:103–110
  9. Machtay M, Swann S, Komaki R, et al. Higher BED is associated with improved local-regional control and survival for NSCLC treated with chemoradiotherapy: An RTOG Analysis. Int J Radiat Oncol Biol Phys. 2005;63:S40
  10. Rengan R, Rosenzweig KE, Venkatraman E, et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;60:741–747
  11. Wang L, Zhao L, Correa C, et al. Radiation dose is an independent predictor for overall survival in patients with stage III unresectable non-small cell lung cancer treated by radiation with and without chemotherapy. Int J Radiat Oncol Biol Phys. 2007;69:S59
  12. Yuan S, Sun X, Li M, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol. 2007;30:239–244
  13. De Ruysscher D, Wanders S, van Haren E, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: A prospective clinical study. Int J Radiat Oncol Biol Phys. 2005;62:988–994
  14. Martel MK, Sahijdak WM, Hayman JA, et al. Incidental dose to clinically negative nodes from conformal treatment fields for nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1999;45:S244
  15. Jeremic B. Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in nonsmall cell lung cancer (NSCLC). Enough to convert no-elective into elective nodal irradiation (ENI)?. Radiother Oncol. 2004;71:123–125
  16. Chen M, Hayman JA, Ten Haken RK, et al. Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: Is low incidence of regional failure due to incidental nodal irradiation?. Int J Radiat Oncol Biol Phys. 2006;64:120–126
  17. Chapet O, Haken RK, Quint L, et al. Incidental irradiation to non-involved nodal stations in patients with Stage III non-small cell lung cancer treated with 3-D conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2006;69:S474–S475
  18. Chapet O, Kong FM, Quint LE, et al. CT-based definition of thoracic lymph node stations: An atlas from the University of Michigan. Int J Radiat Oncol Biol Phys. 2005;63:170–178
  19. Jeremic B. Low incidence of isolated nodal failures after involved-field radiation therapy for non small-cell lung cancer: Blinded by the light?. J Clin Oncol. 2007;25:5543–5545
  20. Chen ZL, Perez S, Holmes EC, et al. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. J Natl Cancer Inst. 1993;85:493–498
  21. Passlick B, Izbicki JR, Kubuschok B, et al. Detection of disseminated lung cancer cells in lymph nodes: Impact on staging and prognosis. Ann Thorac Surg. 1996;61:177–182
  22. Dobashi K, Sugio K, Osaki T, et al. Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: Prognostic significance. J Thorac Cardiovasc Surg. 1997;114:339–346
  23. Maruyama R, Sugio K, Mitsudomi T, et al. Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997;114:535–543
  24. Perez CA, Stanley K, Grundy G, et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: Report by the Radiation Therapy Oncology Group. Cancer. 1982;50:1091–1099
  25. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 1990;8:1543–1555
  26. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210–1215
  27. Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys. 1991;20:1183–1190
  28. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–530
  29. Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999;52:137–148
  30. Jeremic B, Milicic B, Acimovic L, et al. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: Long-term results of a phase II study. J Clin Oncol. 2005;23:1144–1151
  31. Rocmans P, Emami B, Cox JD, et al. Quality control in NSCLC treatment: A consensus report. Lung Cancer. 1991;7:S19–S20
  32. Emami B, Scott C, Byhardt R, et al. The value of regional nodal radiotherapy (dose/volume) in the treatment of unresectable non-small cell lung cancer: An RTOG analysis. Int J Radiat Oncol Biol Phys. 1996;36:S209
  33. Emami B, Mirkovic N, Scott C, et al. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: An analysis of RTOG data. Lung Cancer. 2003;41:207–214
  34. Dosoretz DE, Katin MJ, Blitzer PH, et al. Radiation therapy in the management of medically inoperable carcinoma of the lung: Results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys. 1992;24:3–9
  35. Kupelian PA, Komaki R, Allen P. Prognostic factors in the treatment of node-negative nonsmall cell lung carcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 1996;36:607–613
  36. Sibley GS, Jamieson TA, Marks LB, et al. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: The Duke experience. Int J Radiat Oncol Biol Phys. 1998;40:149–154
  37. Morita K, Fuwa N, Suzuki Y, et al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: A retrospective analysis of 149 patients. Radiother Oncol. 1997;42:31–36
  38. Glazer GM, Orringer MB, Gross BH, et al. The mediastinum in non-small cell lung cancer: CT-surgical correlation. AJR Am J Roentgenol. 1984;142:1101–1105
  39. Heavey LR, Glazer GM, Gross BH, et al. The role of CT in staging radiographic T1N0M0 lung cancer. AJR Am J Roentgenol. 1986;146:285–290
  40. Conces DJ, Klink JF, Tarver RD, et al. T1N0M0 lung cancer: Evaluation with CT. Radiology. 1989;170:643–646
  41. Martini N, Beattie EJ. Results of surgical treatment in Stage I lung cancer. J Thorac Cardiovasc Surg. 1977;74:499–505
  42. Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988;96:440–447
  43. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60:615–622
  44. Koike T, Terashima M, Takizawa T, et al. Clinical analysis of small-sized peripheral lung cancer. J Thorac Cardiovasc Surg. 1998;115:1015–1020
  45. Wu J, Ohta Y, Minato H, et al. Nodal occult metastasis in patients with peripheral lung adenocarcinoma of 2.0 cm or less in diameter. Ann Thorac Surg. 2001;71:1772–1777
  46. Sawyer TE, Bonner JA, Gould PM, et al. Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: Implications in the inoperable and three-dimensional dose-escalation settings. Int J Radiat Oncol Biol Phys. 1999;43:965–970
  47. Suzuki K, Nagai K, Yoshida J, et al. Predictors of lymph node and intrapulmonary metastasis in clinical stage IA non-small cell lung carcinoma. Ann Thorac Surg. 2001;72:352–356
  48. Suzuki K, Nagai K, Yoshida J, et al. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg. 1999;117:593–598
  49. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. Radiology. 1999;213:530–536
  50. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis. Ann Intern Med. 2003;139:879–892
  51. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA. 2001;285:914–924
  52. Annema JT, Versteegh MI, Veselic M, et al. Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging. J Clin Oncol. 2005;23:8357–8361
  53. de Langen AJ, Raijmakers P, Riphagen I, et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: A meta-analysis. Eur J Cardiothorac Surg. 2006;29:26–29
  54. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853–863
  55. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 2002;62:51–60
  56. Steenbakkers RJHM, Duppen JC, Fitton I, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: A three-dimensional analysis. Int J Radiat Oncol Biol Phys. 2006;64:435–448
  57. Mah K, Caldwell CB, Ung YC, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: A prospective study. Int J Radiat Oncol Biol Phys. 2002;52:339–350
  58. Zhao L, Chen M, Ten Haken R, et al. Three-dimensional conformal radiation may deliver considerable dose of incidental nodal irradiation in patients with early stage node-negative non-small cell lung cancer when the tumor is large and centrally located. Radiother Oncol. 2007;82:153–159
  59. Schwarz M, Alber M, Lebesque JV, et al. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;62:561–570
  60. Zhang HX, Yin WB, Zhang LJ, et al. Curative radiotherapy of early operable non-small cell lung cancer. Radiother Oncol. 1989;14:89–94
  61. Talton BM, Constable WC, Kersh CR. Curative radiotherapy in non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1990;19:15–21
  62. Hayakawa K, Mitsuhashi N, Nakajima N, et al. Radiation therapy for stage I-III epidermoid carcinoma of the lung. Lung Cancer. 1992;8:213–223
  63. Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol. 1996;41:41–44
  64. Hayakawa K, Mitsuhashi N, Saito Y, et al. Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer. Lung Cancer. 1999;26:137–142
  65. Wolthaus JW, Schneider C, Sonke JJ, et al. Mid-ventilation CT scan construction from four-dimensional respiration-correlated CT scans for radiotherapy planning of lung cancer patients. Int J Radiat Oncol Biol Phys. 2006;65:1560–1571
  66. Morrison R, Delley TJ, Cleland WP. The treatment of carcinoma of the bronchus. A clinical trial to compare surgery and supervoltage radiotherapy. Lancet. 1963;7283:683–684
  67. Haffty BG, Goldberg NB, Gerstley J, et al. Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1988;15:69–73
  68. Kaskowitz L, Graham MV, Emami B, et al. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1993;27:517–523
  69. Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiother Oncol. 1997;43:29–37
  70. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer. Radiother Oncol. 1999;51:141–145
  71. Rosenzweig KE, Sura S, Jackson A, et al. Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol. 2007;25:5557–5561
  72. Belderbos JSA, Boersma JL, Lebesque JV. Elective nodal irradiation in non-small cell lung cancer. In:  Mornex F,  van Houtte P editor. Treatment optimization for lung cancer from classical to innovative procedures—IASLC International Workshop, 24–26 June, 1998. Amsterdam: Elsevier; 1998;p. 99–102
  73. Grills IS, Yan D, Martinez AA, et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: A comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys. 2003;57:875–890
  74. Fu XL, Jiang GL, Wang LJ, et al. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: Clinical phase I/II trial. Int J Radiat Oncol Biol Phys. 1997;39:545–552
  75. Fang LC, Komaki R, Allen P, et al. Comparison of outcomes for patients with medically inoperable stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:108–116
  76. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev. 2001;CD002935
  77. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial. J Clin Oncol. 2001;19:127–136
  78. Rosenzweig KE, Sim SE, Mychalczak B, et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:681–685
  79. Kepka L, Bujko K, Zolciak-Siwinska A. Risk of isolated nodal failure for non-small cell lung cancer (NSCLC) treated with the elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) techniques. Acta Oncol. 2008;47:95–103
  80. De Ruysscher D, Bremer RH, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: A phase II trial. Radiother Oncol. 2006;80:307–312
  81. Jeremic B, Classen J, Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54:119–130
  82. Williams TE, Thomas CR, Turrisi AT. III. Counterpoint: Better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation. Semin Radiat Oncol. 2000;10:315–323
  83. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–1631
  84. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839
  85. Zimmermann FB, Geinitz H, Schill S, et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol. 2006;45:796–801
  86. McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: Phase I study. Int J Radiat Oncol Biol Phys. 2005;63:1010–1015
  87. International Commission on Radiation Units and Measurements . ICRU Report 62. Prescribing, recording and reporting photon beam therapy. (Supplement to ICRU Report 50). Bethesda, MD: ICRU; 1999;
  88. Giraud P, De Rycke Y, Lavole A, et al. Probability of mediastinal involvement in non-small-cell lung cancer: A statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy?. Int J Radiat Oncol Biol Phys. 2006;64:127–135
  89. Senan S, De Ruysscher D, Giraud P, et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol. 2004;71:139–146
  90. National Collaborating Centre for Acute Care at the Royal College of Surgeons of England. The diagnosis and treatment of lung cancer. CG24 lung cancer full guideline. Available online at: http://www.nice.org.uk/nicemedia/pdf/cg024fullguideline.pdf. 2005. Accessed June 19, 2008.
  91. Scottish Intercollegiate Guidelines Network. Management of patients with lung cancer. Available online at: http://www.sign.ac.uk/pdf/qrg80.pdf. 2005. Accessed June 19, 2008.
  92. Casas F, Vinolas N, Sanchez-Reyes A, et al. Spanish patterns of care for 3D radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:138–142
  93. Kepka L, Danilova V, Saghatelyan T, et al. Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: Results of an International Atomic Energy Agency (IAEA) survey. Lung Cancer. 2007;56:235–245

 Conflict of interest: none.

PII: S0360-3016(08)02469-3

doi: 10.1016/j.ijrobp.2008.04.081

International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 335-342 , 1 October 2008

Article Tools